Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Open accessThe DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.
Abstract
Dasatinib (BMS-354825), a novel dual SRC/BCR-ABL kinase inhibitor, exhibits greater potency than imatinib mesylate (IM) and inhibits the majority of kinase mutations in IM-resistant chronic myeloid leukemia (CML). We have previously demonstrated that IM reversibly blocks proliferation but does not induce apoptosis of primitive CML cells. Here, we have attempted to overcome this resistance with dasatinib. Primitive IM-resistant CML cells showed only single-copy BCR-ABL but expressed significantly higher BCR-ABL transcript levels and BCR-ABL protein compared with more mature CML cells (P = .031). In addition, CrKL phosphorylation was higher in the primitive CD34+CD38– than in the total CD34+ population (P = .002). In total CD34+ CML cells, IM inhibited phosphorylation of CrKL at 16 but not 72 hours, consistent with enrichment of an IM-resistant primitive population. CD34+CD38– CML cells proved resistant to IM-induced inhibition of CrKL phosphorylation and apoptosis, whereas dasatinib led to significant inhibition of CrKL phosphorylation. Kinase domain mutations were not detectable in either IM or dasatinib-resistant primitive CML cells. These data confirm that dasatinib is more effective than IM within the CML stem cell compartment; however, the most primitive quiescent CML cells appear to be inherently resistant to both drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even potent TKIs are unable to eradicate CML-LSCs,6,7 which are the main culprit of disease relapse upon TKI discontinuation.”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291 · cited 1×
“17,49 To compare the antiproliferative properties of IM with those of dasatinib and to assess the net effect of these drugs alone and in combination on total and CFSEmax cells, 6 test conditions were assayed: (1) no drug control, (2) IM alone for 6 days (5 M), (3) dasatinib alone for 6 days (150 nM), (4) IM for 3 days…”
MethodO'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Mellor, D. H. (1981) · Cited by 1,981
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756 · cited 1×
“17,49 To compare the antiproliferative properties of IM with those of dasatinib and to assess the net effect of these drugs alone and in combination on total and CFSEmax cells, 6 test conditions were assayed: (1) no drug control, (2) IM alone for 6 days (5 M), (3) dasatinib alone for 6 days (150 nM), (4) IM for 3 days…”
MethodShah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
GROFFEN, J., STEPHENSON, J., HEISTERKAMP, N., DEKLEIN, A., BARTRAM, C., & GROSVELD, G. (1984) · Cell · doi:10.1016/0092-8674(84)90077-1 · Cited by 1,599
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Research works printed but not linked: 2
- Clark RE, Knight K, Lucas CM, Pirmohamed M, Wang L. Expression of the imatinib drug transporters HOCT1 and MDR1 levels determines imatinib response and development of Bcr-Abl kinase mutations in chronic myeloid leukemia (CML). Exper Hematol.2005;33: 51-52.
- Jiang X, Zhao Y, Chan WY, et al. Bcr-Abl transcripts are present at the highest level in the most primitive lin–CD34+CD38– leukemic cells from CML patients with chronic phase disease and then progressively decrease as they differentiate [abstract]. Blood.2003;102: 418a.
Cited by
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
“Additionally, it has been shown in several haematological tumours that quiescent stem cells are refractory to tyrosine kinase inhibitors, and these cell populations are probably also involved in resistance mechanism”
Jordan, C. T., Guzman, M. L., & Noble, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra061808 · Cited by 1,702
Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Molecular biology of bcr-abl1–positive chronic myeloid leukemia
Quintás-Cardama, A., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-03-144790 · Cited by 745
Metadata
- Authors
- Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L.
- Affiliations
- Glasgow Royal Infirmary (GB)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-06-01
- Volume
- 107
- Issue
- 11
- Pages
- 4532-4539
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2149468947
- Cited by
- 635
- References
- 63
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 6 · 2023: 13 · 2022: 12 · 2021: 13 · 2020: 18 · 2019: 20 · 2018: 15 · 2017: 33 · 2016: 37 · 2015: 22 · 2014: 32 · 2013: 56 · 2012: 49
- FWCI
- 35.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Novartis Pharma
- Medical Research Council
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- dasatinib, imatinib resistance, chronic myeloid leukemia, BCR-ABL tyrosine kinase, Src family kinases, CrkL phosphorylation, apoptosis, kinase domain mutations
- MeSH terms
- Imatinib Mesylate, Dasatinib, Benzamides, Humans, Nuclear Proteins, Phosphorylation, Piperazines, Pyrimidines, RNA, Neoplasm, Thiazoles, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Gene Dosage, HL-60 Cells, Antigens, CD34, Drug Resistance, Neoplasm, K562 Cells, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. https://app.cochat.ai/papers/10.1182/blood-2005-07-2947
- The paper
- Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006). Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. https://doi.org/10.1182/blood-2005-07-2947
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.